Sporadic Alzheimer's disease (SAD) accounts for over 95% of all AD cases, distinguishing itself from familial AD through its complex polygenic architecture and multifactorial etiology. Unlike familial AD caused by deterministic mutations in APP, PSEN1, or PSEN2, sporadic AD arises from the interplay of multiple genetic risk variants, age-related changes, and environmental factors. Karch et al., Neuron (2014) Bellenguez et al., Nat Genet (2022) The challenge of the second century in AD research continues to drive new therapeutic approaches. Holtzman et al., Sci Transl Med (2011) New genetic insights have revealed the complex architecture underlying sporadic disease. Bertram & Tanzi, Science (2010) Ridge et al., Biomed Res Int (2013)
Sporadic Alzheimer's disease (SAD) represents the most prevalent form of neurodegenerative dementia, accounting for over 95% of all AD cases worldwide. Unlike familial AD, which results from deterministic mutations in APP, PSEN1, or PSEN2 genes, SAD develops through a complex interplay of polygenic risk variants, age-related brain changes, and environmental factors. Scheltens et al., Lancet (2021) The disease typically manifests after age 65, with prevalence increasing exponentially with advancing age. van der Flier & Scheltens, Nat Rev Neurol (2015) Knopman et al., Nat Rev Dis Primers (2024) Neuropathological alterations reveal the hallmark features of AD in sporadic cases. Serrano-Pozo et al., Cold Spring Harb Perspect Med (2011) The amyloid hypothesis remains central to understanding SAD pathogenesis. Selkoe & Hardy, EMBO Mol Med (2016) Inconsistencies and controversies continue to refine our understanding. Morris et al., Acta Neuropathol Commun (2014)
The APOE ε4 allele represents the strongest genetic risk factor for SAD: Jansen et al., JAMA (2015) Mott et al., Nat Rev Neurol (2024)
Over 40 genetic loci have been associated with SAD, with large-scale GWAS meta-analyses identifying numerous risk loci: Sims et al., Nat Rev Neurol (2023) Wightman et al., Nat Genet (2021) Schwartzentruber et al., Nat Genet (2021)
| Gene | Function | Risk Effect | Source |
|---|---|---|---|
| TREM2 | Microglial activation | 2-4x | Chen et al., Transl Neurodegener (2023) |
| CLU | Complement | 1.2x | Kunkle et al., Nat Genet (2019) |
| PICALM | Clathrin-mediated endocytosis | 1.2x | Lambert et al., Nat Genet (2013) |
| BIN1 | Tau pathophysiology | 1.2x | Wightman et al., Nat Genet (2021) |
| ABCA7 | Lipid transport | 1.2x | Schwartzentruber et al., Nat Genet (2021) |
| CD2AP | Cytoskeletal function | 1.2x | Bellenguez et al., Nat Genet (2022) |
| EPHA1 | Cell adhesion | Protective | Karch et al., Neuron (2014) |
| PLD3 | Lipid metabolism | 1.2x | Kunkle et al., Nat Genet (2019) |
| SORL1 | Endocytic recycling | 1.3x | Seifarath et al., Nat Med (2024) |
Unlike familial AD (increased Aβ production), SAD involves impaired clearance mechanisms: Canter et al., Nature (2016) van der Kant et al., Nat Rev Neurol (2019)
Age-related cellular changes in SAD, including senescent cell accumulation: Hou et al., Nat Rev Neurol (2023)
Microglial activation in SAD, mediated by TREM2 and other pathways: Song et al., Signal Transduct Target Ther (2024) Duong et al., Nat Rev Neurosci (2024) Schilling et al., Brain (2024)
Age-related epigenetic dysregulation: Hernandez et al., Nat Aging (2024) Ulyannikova et al., Aging Cell (2024)
Cerebrovascular dysfunction in SAD, including neurovascular uncoupling: Rosenthal et al., Nat Rev Neurol (2024) Marshall et al., Nat Rev Neurol (2023) van de Velde & van der Flier, Nat Rev Neurol (2018)
Age-related mitochondrial changes in SAD: Gong et al., Transl Neurodegener (2023) Hou et al., Nat Rev Neurol (2023)
Age-related changes in protein clearance, a key feature in SAD pathogenesis: Liu et al., Ageing Res Rev (2024) Hou et al., Nat Rev Neurol (2023)
Modifiable risk factors and lifestyle interventions for SAD prevention: Livingston et al., Lancet (2020) Breijyeh & Karaman, Molecules (2020) Knopman et al., Nat Rev Neurol (2021) Population-level associations between modifiable risk factors and AD incidence provide key insights. Observed associations, Nat Med (2023)
The study of Sporadic Alzheimer'S Disease Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.